Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma

Table 1 Degree of cardia stenosis

Clinical classifications	Diet conditions	Cardia diameters in the barium meal exam (mm)
I	Ordinary diet	8-10
II	Semi-liquid diet	6-8
III	Liquid diet	4-6
IV	No drinking	2-4
V	Saliva refluxing	0-2

Table 2 Patient characteristics at baseline, case (%)

Characteristics	Older group	Control group
	(n = 32)	(n = 38)
Demography
Male/female	24 (75)/8 (25)	29 (76.3)/9 (23.7)
Median age, yr (range)	79.5 (75-89)	64 (55-74)
Karnofsky performance status
Median	80%	80%
100%	1 (3.1)	2 (5.3)
90%	10 (31.2)	13 (34.2)
80%	17 (53.2)	18 (47.4)
60%-70%	4 (12.5)	5 (13.1)
Weight loss > 5%	11 (34.4)	13 (34.2)
Cardia stenosis status
I-II	0	0
III	25 (78.1)	29 (76.3)
IV	6 (18.8)	8 (21.1)
V	1 (3.1)	1 (2.6)
Histological grade
G1-2	17 (53.1)	19 (50)
G3	12 (37.5)	14 (36.8)
Others (grade not stated)	3 (9.4)	5 (13.2)
Extent of disease
Metastatic	10 (31.3)	12 (31.6)
Locally advanced	22 (68.7)	26 (68.4)
Metastatic site
Lymph nodes	10 (31.3)	12 (31.6)
Liver	3 (9.4)	3 (7.9)
Peritoneum	1 (3.1)	2 (5.3)
Lung	0	1 (2.6)
Others	0	0
No. of metastatic sites
1	6 (18.8)	6 (15.8)
≥ 2	4 (12.5)	6 (15.8)

Table 3 Comparisons of chemotherapy sensitivity, case (%)

Clinical groups	CR	PR	SD	PD	CR + PR
Older group (n = 32)	3 (9.4)	18 (56.2)	11 (34.4)	0	21 (65.6)a
Control group (n = 38)	4 (10.5)	22 (57.9)	12 (31.6)	0	26 (68.4)

^aχ² = 0.062, P = 0.804 vs control group. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 4 Comparisons of symptom (dysphagia) improvement, case (%)

Clinical groups	CR	PR	NC	PD	CR + PR
Older group (n = 32)	5 (15.6)	20 (62.5)	7 (21.9)	0 (0)	25 (78.1)a
Control group (n = 38)	5 (13.2)	24 (63.2)	9 (23.7)	0 (0)	29 (76.3)

^aχ² = 0.032, P = 0.857 vs control group. CR: Complete response; PR: Partial response; NC: No change; PD: Progressive disease.

Table 5 Comparisons of short-term chemotherapy effects, case (%)

Clinical groups	CR	PR	SD	PD	CR+PR
Older group (n = 32)	5 (15.6)	17 (53.2)	8 (25)	2 (6.2)	22 (68.8)a
Control group (n = 38)	5 (13.2)	20 (52.6)	10 (26.3)	3 (7.9)	25 (65.8)

^aχ² = 0.069, P = 0.793 vs control group. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 6 Comparisons of chemotherapy side effects, case (%)

Side effect	Older group (n = 32)			Control group (n = 38)			P1 value
	I-IV	III	IV	I-IV	III	IV
Leukopenia	25 (78.1)	3 (9.3)	0	28 (73.7)	4 (10.5)	0	0.666
Anemia	24 (75.0)	2 (6.2)	0	27 (71.1)	2 (5.3)	0	0.900
Thrombocytopenia	23 (71.9)	1 (3.1)	0	27 (71.1)	1 (2.6)	0	0.940
Fever	2 (6.3)	0	0	3 (7.9)	0	0	1.000
Oral mucositis	13 (40.6)	0	0	14 (36.8)	0	0	0.746
Nausea/vomiting	10 (31.3)	0	0	11 (28.9)	0	0	0.834
Diarrhea	14 (43.8)	0	0	16 (42.1)	0	0	0.890
Fatigue	21 (65.6)	2 (6.3)	0	23 (60.5)	1 (2.6)	0	0.660
Sensory neuropathy	18 (56.3)	0	0	21 (55.3)	0	0	0.934
Liver function (ALT/AST)	4 (12.5)	0	0	3 (7.9)	0	0	0.810
Renal function (BUN/Cr)	1 (3.1)	0	0	0	0	0	-
Hand-foot syndrome	0	0	0	0	0	0	-
Myocardial ischemia	0	0	0	0	0	0	-
Anaphylaxis	0	0	0	0	0	0	-

¹P value for gradeI-IV between older group and control group. ALT: Alanine transaminase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; Cr: Creatine.